 |
|
|
Dry Overactive Bladder - A Precursor to 'Wet Overactive Bladder'?
|
|
|
|
|
| Description: |
Introduction
Dry Overactive Bladder (dry OAB) is considered part of the overactive bladder syndrome. However, unlike wet overactive bladder (or urge urinary incontinence), it is normally only associated with urinary urgency and frequency, and not incontinence. Even so, recent studies suggest that these symptoms bother patients, with unpredictable urges disrupting daily activities and quality of life.
Scope
Quantitative treatment data from 365 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments.
Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and treatment strategy for dry OAB.
Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin.
Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline
Highlights.
Opinion leaders often recognize the impact that urge and frequency symptoms can have on a patient, even in the absence of incontinence episodes. However, prescribing physicians in general do not all accept this readily, leading to under prescribing in this patient group.
For many years the terms urge urinary incontinence (UUI) and dry OAB have been used to describe separate syndromes with similar symptoms differentiated by the occurrence or not of incontinence. In fact is may be more suitable to consider overactive bladder as a continuum.
Although pharmacological therapy is used less frequently in dry OAB than in UUI, the products chosen are similar, based on their activity on urge and frequency via detrusor activity; occasionally a less effective product with lower side effects may be chosen for dry OAB as opposed to a stronger, but less well tolerated product for UUI.
Reasons to Purchase
Forecast product sales by understanding key aspects of dry OAB epidemiology, diagnosis and treatment.
Gain a better understanding of the challenges facing current and future players in the dry OAB market.
Identify physicians key concerns in dry OAB including unmet needs and the attributes that physicians believe are desirable for future treatments. |
|
| |
|
|
| Source: |
Datamonitor |
|
| Type: |
Report |
|
| Doc Number: |
DMHC2211 |
|
| Format: |
Slide Pack |
|
| Pages: |
50 |
|
| Publication
Date: |
20-Apr-06 |
|
| Price: |
US$
3,800 |
|
 |
Table of Contents >> |
|
 |
To order the complete report,
please call: 610.356.1067 |
|
|
Public
Feeds 
